Companies / ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc.

Nasdaq: ALXOCIK 1810182SOUTH SAN FRANCISCO, CA

Financials · FY2022

Revenue$0
Net income$-101.69M
Total debt$10.20M
Cash$22.69M
Diluted EPS$-1.90
Shares outstanding138.3M

Ownership

138.3M shares outstanding · as of Jul 30, 2026
6.4%Insiders
Ownership
Insiders6.39%8,833,452
Institutions47.28%65,372,586
Public float46.34%64,070,959

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 10

View all →
Insider% of sharesShares
Goodman Corey SDirector · 10% owner
6.11%8,453,038
Lettmann JasonCEOCHIEF EXECUTIVE OFFICER · Director
0.21%293,609
Pinto ShellySVP, FINANCE AND CAO
0.06%86,805
Curran Daniel J.Director
——
Garland J. ScottDirector
——
Hemrajani RekhaDirector
——
Klencke BarbaraChief Medical Officer
——
Sandler Alan B.Director
——
Shantharam HarishChief Financial Officer
——
Takimoto Chris HDirector
——

Institutional holders 66

View all →
HolderValue% of shares
RA Capital Management, L.P.$26.09M9.41%
BlackRock, Inc.$15.32M5.35%
Blackstone Inc$11.71M4.21%
venBio Partners LLC$10.96M7.01%
Marshall Wace, LLP$7.51M2.72%
Orbimed Advisors LLC$5.75M2.07%
Adage Capital Partners Gp, L.L.C.$4.01M1.45%
Millennium Management LLC$3.99M1.44%
Redmile Group, LLC$3.69M2.36%
Two Sigma Investments, LP$3.18M1.15%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Feb 2, 2026Goodman Corey S
Director
BuyCommon Stock$5.00M+3.2M
+60.45%
8,453,038
6.11% of shares
high
Mar 19, 2026Lettmann Jason
CEO
SellCommon Stock$26.7K-12K
-4.02%
293,609
0.21% of shares
low
Feb 17, 2026Lettmann Jason
CEO
OtherCommon Stock$5.0K-2K
-0.71%
305,920
0.22% of shares
low
Jan 6, 2026Pinto Shelly
Executive
SellCommon Stock$4.4K-4K
-4.26%
88,273
0.06% of shares
low
Mar 19, 2026Pinto Shelly
Executive
SellCommon Stock$2.0K-903
-1.03%
86,805
0.06% of shares
low
Feb 18, 2026Pinto Shelly
Executive
SellCommon Stock$1.3K-565
-0.64%
87,708
0.06% of shares
low
Jan 20, 2026Sandler Alan B.
Director
GrantStock option (right to buy)—+10K
10,100
<0.01% of shares
low
Mar 3, 2026Klencke Barbara
Executive
GrantStock option (right to buy)—+700K
700,000
0.51% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
RA Capital Management, L.P.Passive13G———
TCG Crossover GP II, LLCPassive13G———
HBM Healthcare Investments (Cayman) Ltd.Passive13G/A———
Millennium Management LLCPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
ALXO——00166B105—